Levetiracetam

Levetiracetam (UCB L059) is a novel anticonvulsant with antihyperalgesic efficacy in inflammatory pain. (In Vitro) :Levetiracetam increases the transcription of HDACs and recruits corepressor complex on O6-Methylguanine-DNA-methyltransferase (MGMT) promoter, thus silencing its activity.Levetiracetam sensitizes (40 μg/mL) glioblastoma multiforme stem-like cells (GSCs) to Temozolomide (250 μM) treatment.MGMT expression is downregulated in GCSCs treated with Levetiracetam (40 μg/mL) (In Vivo) :Levetiracetam (10, 25, or 50 mg/kg) suppresses behavioral and electrographic seizure activity during neonatal hypoxia.